View Older Stories
-
Medline Inc (MDLN) PT Lowered to $45 at Barclays, 'Material input costs are the biggest swing factor in F26'
-
Medline's secondary share offering was multiple times oversubscribed
-
Medline launches spay/neuter surgical packs for animal health market
-
Medline (MDLN) files for 60M share offering by selling stockholders
-
Medline Inc (MDLN) PT Raised to $62 at Tigress Financial Partners
-
Medline Inc (MDLN) PT Lowered to $54 at Bernstein SocGen Group
-
Medline Inc. (MDLN) Reports Q1 EPS of $0.33
-
BTIG highlights key trends from Boston Digital Health Summit
-
Medline launches AI-powered supply chain platform Mpower
-
Medline partners with Symbotic for AI warehouse automation technology
-
Medline breaks ground on 1.2 million sq ft distribution center in Texas
-
Citi Resumes Medline Inc (MDLN) at Buy
-
Medline Inc (MDLN) PT Raised to $60 at Tigress Financial Partners
-
BTIG Reiterates Buy Rating on Medline Inc (MDLN)
-
Medline Inc (MDLN) PT Raised to $54 at BMO Capital
-
Medline Inc (MDLN) PT Raised to $55 at Wolfe Research
-
Medline Inc. (MDLN) Reports Q4 Loss of $0.01
-
Medline Inc (MDLN) PT Raised to $55 at Stifel
-
Medline Inc (MDLN) PT Raised to $56 at Leerink Partners
-
Medline Inc (MDLN) PT Raised to $55 at Evercore ISI
-
FDA: Medline has identified electrical safety risks with its Medline Basic Homecare beds that may lead to fire
-
Tigress Financial Partners Starts Medline Inc (MDLN) at Buy
-
Citi Starts Medline Inc (MDLN) at Sell
-
BNP Paribas Exane Starts Medline Inc (MDLN) at Neutral
-
Deutsche Bank Starts Medline Inc (MDLN) at Hold
-
Nephron Starts Medline Inc (MDLN) at Hold
-
Wells Fargo Starts Medline Inc (MDLN) at Equal Weight
-
BofA Securities Starts Medline Inc (MDLN) at Buy
-
BTIG Starts Medline Inc (MDLN) at Buy
-
Wolfe Research Starts Medline Inc (MDLN) at Outperform
-
TD Cowen Starts Medline Inc (MDLN) at Buy
-
William Blair Starts Medline Inc (MDLN) at Outperform
-
Mizuho Starts Medline Inc (MDLN) at Outperform
-
Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
-
Barclays Starts Medline Inc (MDLN) at Overweight
-
Rothschild Redburn Starts Medline Inc (MDLN) at Neutral
-
Truist Securities Starts Medline Inc (MDLN) at Buy
-
Morgan Stanley Starts Medline Inc (MDLN) at Overweight
-
Jefferies Starts Medline Inc (MDLN) at Buy
-
BMO Capital Starts Medline Inc (MDLN) at Outperform
-
Stifel Starts Medline Inc (MDLN) at Buy
-
JPMorgan Starts Medline Inc (MDLN) at Overweight
-
UBS Starts Medline Inc (MDLN) at Buy
-
Baird Starts Medline Inc (MDLN) at Outperform
-
Evercore ISI Starts Medline Inc (MDLN) at Outperform
-
Piper Sandler Starts Medline Inc (MDLN) at Overweight
-
RBC Capital Starts Medline Inc (MDLN) at Outperform
-
Leerink Partners Starts Medline Inc (MDLN) at Outperform
-
Bernstein SocGen Group Starts Medline Inc (MDLN) at Outperform
-
Goldman Sachs Starts Medline Inc (MDLN) at Buy

